The TERT promoter mutations were mainly detected in urinary bladder cancer (66%), hepatocellular carcinoma (54%), pancreato-biliary cancer (15%), and malignant melanoma (13%), and the overall incidence was similar to that reported previously [3, 6–8, 35, 42]. This evidence concerns the gene TERT and melanoma.